News from boehringer ingelheim pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

May 19, 2016, 11:41 ET Boehringer Ingelheim presenta el sorteo "Conoce a Don Francisco"

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) anunció hoy el lanzamiento del sorteo "Conoce a Don Francisco" que ofrece la oportunidad de...


May 19, 2016, 10:41 ET Boehringer Ingelheim Launches "Conoce a Don Francisco" Sweepstakes

Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced today that it is launching the "Conoce a Don Francisco" sweepstakes, offering a chance...


May 16, 2016, 08:00 ET New Presentations at ATS 2016 Reinforce OFEV® (nintedanib) Efficacy, Safety and Tolerability Across Range of Patients with IPF

New analyses presented at the American Thoracic Society's 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of...


Apr 13, 2016, 08:00 ET Head-to-head study demonstrating Gilotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology

 Results from LUX-Lung 7, a global head-to-head Phase IIb trial comparing treatment with Gilotrif® (afatinib) to Iressa® (gefitinib)...


Apr 02, 2016, 11:30 ET Interim Phase III Data Show Praxbind® (idarucizumab) Reverses Dabigatran (Pradaxa®) in Emergency Situations

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the results of a new interim analysis of data from the ongoing phase III RE-VERSE...


Mar 31, 2016, 09:00 ET The 4WARD Coalition™ Launches AFib4WARD.com to Encourage Shared Decision Making Between AFib Patients and Healthcare Providers

 Today the 4WARD Coalition launched AFib4WARD.com, an online tool designed to help non-valvular atrial fibrillation (AFib) patients and their...


Mar 29, 2016, 08:00 ET FDA Approves Supplemental New Drug Application (sNDA) for Boehringer Ingelheim's STIOLTO RESPIMAT for COPD Health-Related Quality of Life

 Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) approved a sNDA for STIOLTO...


Mar 23, 2016, 08:00 ET Boehringer Ingelheim Launches Observational Study on Management of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) with Pradaxa® (dabigatran etexilate mesylate)

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the enrollment of the first patient in RE-COVERY DVT/PE™, a global...


Mar 23, 2016, 07:00 ET Propeller Health and Boehringer Ingelheim Announce New Partnership Focused on Improving Adherence and Care Management for People Living with COPD and Asthma

 Propeller Health, the leading digital health solution for respiratory medicine, and Boehringer Ingelheim Pharmaceuticals Inc., a global...


Mar 08, 2016, 08:00 ET Praxbind® (idarucizumab), Specific Reversal Agent for Pradaxa® (dabigatran etexilate mesylate), Now Stocked in More Than 2,200 Hospitals

Today, Boehringer Ingelheim announced that Praxbind® (idarucizumab), a specific reversal agent for Pradaxa® (dabigatran etexilate...


Feb 25, 2016, 08:00 ET New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations

Pooled analysis from the TOMORROW and INPULSIS® trials, recently published in Respiratory Medicine, confirmed that OFEV reduces the risk of...


Feb 18, 2016, 08:00 ET Country Music Artist Joe Nichols Raises Awareness of Rare Lung Disease That Claimed His Father's Life and Leaves Those Affected "Breathless"

 Award-winning country music artist, Joe Nichols is teaming up with Boehringer Ingelheim Pharmaceuticals, Inc. to raise awareness of the...


Feb 09, 2016, 08:00 ET Newly Published Head-to-Head Data Show STIOLTO RESPIMAT Improved Lung Function Across Range of Measures

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the publication of data that show STIOLTO RESPIMAT improved lung function across a range...


Feb 03, 2016, 08:00 ET SPIRIVA RESPIMAT Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that SPIRIVA RESPIMAT is now available by prescription for the treatment of asthma...


Dec 14, 2015, 08:00 ET First Multinational Study Initiated to Evaluate OFEV® (nintedanib) with Add-on of pirfenidone in the Treatment of Idiopathic Pulmonary Fibrosis

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced the initiation of a new 12-week study (ClinicalTrials.gov Identifier: NCT02579603)...


Dec 08, 2015, 08:00 ET New Phase III Study of Nintedanib in People with Systemic Sclerosis and Lung Fibrosis Launched

 Boehringer Ingelheim announced today that the first person has been enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in...


Nov 23, 2015, 10:24 ET FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Prophylaxis of Deep Venous Thrombosis (DVT) and Pulmonary Embolism (PE) after Hip Replacement Surgery

 Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved...


Nov 18, 2015, 11:30 ET Boehringer Ingelheim Awarded Perfect Score on Human Rights Campaign Foundation's Corporate Equality Index

 Boehringer Ingelheim announced today that it has been recognized on the 2016 Corporate Equality Index (CEI). This is the eighth time that the...


Nov 13, 2015, 04:00 ET New Analyses Further Add to the Efficacy and Safety Profile of OFEV® (nintedanib) in Idiopathic Pulmonary Fibrosis (IPF)

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the presentation of new analyses of OFEV for the treatment of idiopathic pulmonary...


Nov 10, 2015, 08:30 ET Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab

 Boehringer Ingelheim today announced it has completed enrollment for the pivotal Phase III trial (NCT02137226) of BI695501, a biosimilar...


Nov 10, 2015, 08:01 ET Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research

 Boehringer Ingelheim today announced new collaborations with four major scientific partners to enrich research and development of novel...


Nov 09, 2015, 14:45 ET Boehringer Ingelheim Presents New Praxbind® (idarucizumab) Analyses on Reintroduction of Antithrombotic Therapy after Reversal of Dabigatran

Today, Boehringer Ingelheim announced results from two new analyses evaluating...


Nov 09, 2015, 14:00 ET Real-World Analysis of More Than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® (dabigatran etexilate mesylate) in Routine Clinical Care

 Brigham and Women's Hospital in Boston and Boehringer Ingelheim today announced the results of a new interim analysis from a long-term study...


Nov 09, 2015, 10:45 ET New Jardiance® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline

 New sub-analysis data presented today showed the reduction in risk for hospitalization for heart failure or cardiovascular death with...


Nov 08, 2015, 10:17 ET Boehringer Ingelheim Highlights Latest Community and Research Initiatives in Advancing Anticoagulation Care at American Heart Association (AHA) Scientific Sessions 2015

 Today at the American Heart Association (AHA) Scientific Sessions 2015, Boehringer Ingelheim Pharmaceuticals, Inc. announced two key...